288 results on '"E. Goffin"'
Search Results
2. On the optimal z-score threshold for SISCOM analysis to localize the ictal onset zone
- Author
-
Liesbeth De Coster, Koen Van Laere, Evy Cleeren, Kristof Baete, Patrick Dupont, Wim Van Paesschen, and Karolien E. Goffin
- Subjects
Epilepsy ,SISCOM ,Z-score threshold ,Ictal SPECT ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Abstract
Abstract Background In epilepsy patients, SISCOM or subtraction ictal single photon emission computed tomography co-registered to magnetic resonance imaging has become a routinely used, non-invasive technique to localize the ictal onset zone (IOZ). Thresholding of clusters with a predefined number of standard deviations from normality (z-score) is generally accepted to localize the IOZ. In this study, we aimed to assess the robustness of this parameter in a group of patients with well-characterized drug-resistant epilepsy in whom the exact location of the IOZ was known after successful epilepsy surgery. Eighty patients underwent preoperative SISCOM and were seizure free in a postoperative period of minimum 1 year. SISCOMs with z-threshold 2 and 1.5 were analyzed by two experienced readers separately, blinded from the clinical ground truth data. Their reported location of the IOZ was compared with the operative resection zone. Furthermore, confidence scores of the SISCOM IOZ were compared for the two thresholds. Results Visual reporting with a z-score threshold of 1.5 and 2 showed no statistically significant difference in localizing correspondence with the ground truth (70 vs. 72% respectively, p = 0.17). Interrater agreement was moderate (κ = 0.65) at the threshold of 1.5, but high (κ = 0.84) at a threshold of 2, where also reviewers were significantly more confident (p
- Published
- 2018
- Full Text
- View/download PDF
3. Correlation of neuropsychological and metabolic changes after epilepsy surgery in patients with left mesial temporal lobe epilepsy with hippocampal sclerosis
- Author
-
Canan Güvenç, Patrick Dupont, Jan Van den Stock, Laura Seynaeve, Kathleen Porke, Eva Dries, Karen Van Bouwel, Johannes van Loon, Tom Theys, Karolien E. Goffin, and Wim Van Paesschen
- Subjects
FDG-PET metabolism ,Neuropsychological test scores ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Abstract
Abstract Background Epilepsy surgery often causes changes in cognition and cerebral glucose metabolism. Our aim was to explore relationships between pre- and postoperative cerebral metabolism as measured with 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) and neuropsychological test scores in patients with left mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE-HS), who were rendered seizure-free after epilepsy surgery. Results Thirteen patients were included. All had neuropsychological testing and an interictal FDG-PET scan of the brain pre- and postoperative. Correlations between changes in neuropsychological test scores and metabolism were examined using statistical parametric mapping (SPM). There were no significant changes in the neuropsychological test scores pre- and postoperatively at the group level. Decreased metabolism was observed in the left mesial temporal regions and occipital lobe. Increased metabolism was observed in the bi-frontal and right parietal lobes, temporal lobes, occipital lobes, thalamus, cerebellum, and vermis. In these regions, we did not find a correlation between changes in metabolism and neuropsychological test scores. A significant negative correlation, however, was found between metabolic changes in the precuneus and Boston Naming Test (BNT) scores. Conclusions There are significant metabolic decreases in the left mesial temporal regions and increases in the bi-frontal lobes; right parietal, temporal, and occipital lobes; right thalamus; cerebellum; and vermis in patients with left MTLE-HS who were rendered seizure-free after epilepsy surgery. We could not confirm that these changes translate into significant cognitive changes. A significant negative correlation was found between changes in confrontation naming and changes in metabolism in the precuneus. We speculate that the precuneus may play a compensatory role in patients with postoperative naming difficulties after left TLE surgery. Understanding of these neural mechanisms may aid in designing cognitive rehabilitation strategies.
- Published
- 2018
- Full Text
- View/download PDF
4. WCN23-0900 CHRONIC KIDNEY DISEASE IS A KEY RISK FACTOR FOR AORTIC STENOSIS PROGRESSION
- Author
-
A. CANDELLIER, Y. Bohbot, A. Pasquet, M. Diouf, E. Vermes, E. Goffin, M. Gun, F. Peugnet, L. Hénaut, D. Rusinaru, R. Mentaverri, S. Kamel, G. Choukroun, J.L. Vanoverschelde, and C. Tribouilloy
- Subjects
Nephrology - Published
- 2023
5. Les fragilités du patient âgé en dialyse péritonéale : quel impact sur la survie ?
- Author
-
C. Gerontitis, F. Collart, E. Goffin, J.P. Lengele, B. Buysschaert, C. Masset, F. Jouret, S. Gillain, UCL - SSS/IREC/NEFR - Pôle de Néphrologie, and UCL - (SLuc) Service de néphrologie
- Subjects
Nephrology - Published
- 2022
6. Fibrous dysplasia mimicking bone metastasis on
- Author
-
Liesbeth, De Coster, Raf, Sciot, Wouter, Everaerts, Olivier, Gheysens, Raf, Verscuren, Christophe M, Deroose, Steven, Pans, Koen, Van Laere, and Karolien E, Goffin
- Subjects
Male ,Prostatic Neoplasms ,Bone Neoplasms ,Gallium Radioisotopes ,Fibrous Dysplasia of Bone ,Middle Aged ,Magnetic Resonance Imaging ,Multimodal Imaging ,Diagnosis, Differential ,Positron-Emission Tomography ,Humans ,Oligopeptides ,Edetic Acid ,Gallium Isotopes - Published
- 2017
7. Phase 2 Study of
- Author
-
Karolien E, Goffin, Steven, Joniau, Peter, Tenke, Kevin, Slawin, Eric A, Klein, Nancy, Stambler, Thomas, Strack, John, Babich, Thomas, Armor, and Vivien, Wong
- Subjects
Male ,Prostatectomy ,Risk ,Single Photon Emission Computed Tomography Computed Tomography ,Lymphatic Metastasis ,Humans ,Prostatic Neoplasms ,Biological Transport ,Lymph Nodes ,Organotechnetium Compounds ,Middle Aged ,Aged ,Pelvis - Published
- 2017
8. Adéquation en dialyse péritonéale : mise au point
- Author
-
Belkacem Issad, Pierre-Yves Durand, Pascale Siohan, Éric Goffin, Joëlle Cridlig, Guillaume Jean, Jean-Philippe Ryckelynck, W. Arkouche, J.-P. Bourdenx, J. Cridlig, B. Dallaporta, H. Fessy, M. Fischbach, P. Giaime, E. Goffin, B. Issad, G. Jean, D. Joly, L. Mercadal, J.-M. Poux, J.-P. Ryckelynck, P. Siohan, M. Souid, D. Toledano, C. Verger, P. Vigeral, and M. Uzan
- Subjects
Nephrology ,medicine.medical_specialty ,business.industry ,Peritoneal membrane ,medicine.medical_treatment ,Renal function ,Improved survival ,Surgery ,Peritoneal dialysis ,Internal medicine ,Medicine ,Mineral metabolism ,Dialisis peritoneal ,business ,Intensive care medicine ,Cardiovascular mortality - Abstract
The optimal method to assess the adequacy of peritoneal dialysis therapies is controversial. Today, the adequacy must not be considered as a number or a concept assessed only by two parameters (total KT/V urea and total solute clearance) but defined by many more items. In the absence of data, based on theoretical considerations, the reanalysis of the CANUSA study showed that renal kidney function, rather than peritoneal clearance, was associated with improved survival. Residual renal function is considered as a major predictor factor of cardiovascular mortality. Results of this reanalysis were supported by the adequacy data in ADEMEX, EAPOS and ANZDATA studies. Therefore, clinical assessment plays a major role in PD adequacy. The management of fluid balance, the regular monitoring of malnutrition, the control of mineral metabolism and particularly the glucose load, considered as the "corner-stone" of the system, are the main points to be considered in the adequacy of PD patients. The essential goal is to minimize glucose load by glucose-sparing strategies in order to reduce the neoangiogenesis of the peritoneal membrane.
- Published
- 2013
9. Peritoneal dialysis - A
- Author
-
M. Ito, A. Emami-Naini, N. Keyvandarian, F. Moeinzadeh, M. Mortazavi, S. Taheri, K. Io, T. Nishino, Y. Obata, M. Kitamura, S. Abe, T. Koji, S. Kohno, K. Wakabayashi, C. Hamada, T. Nakano, R. Kanda, H. Io, S. Horikoshi, Y. Tomino, M. R. Korte, N. Braun, S. M. Habib, E. Goffin, A. Summers, L. Heuveling, M. G. H. Betjes, M. Lambie, J. Bankart, D. Johnson, R. Mactier, L. Phillips-Darby, N. Topley, S. Davies, F. X. Liu, R. Leipold, M. Arici, U. Farooqui, K.-h. Cho, J.-y. Do, S.-h. Kang, J.-W. Park, K.-W. Yoon, S.-Y. Jung, C. Sise, P. Rutherford, L. Kovacs, S. Konings, M. Pestana, J. Zimmermann, H. Cramp, D. Stein, K. Bang, J. H. Shin, J. Jeong, J.-H. Kim, N. Matsuo, Y. Maruyama, M. Nakao, Y. Tanno, I. Ohkido, H. Hayakawa, H. Yamamoto, K. Yokoyama, T. Hosoya, F. Iannuzzella, M. Corradini, L. Belloni, A. Stefani, M. Parmeggiani, S. Pasquali, O. Svedberg, P. Stenvinkel, A. R. Qureshi, P. Barany, O. Heimburger, P. Leurs, B. Anderstam, J. Waniewski, S. Antosiewicz, D. Baczynski, M. Galach, Z. Wankowicz, M. Prabhu, S. V. Subhramanyam, K. S. Nayak, J.-C. Hwang, M.-Y. Jiang, Y.-H. Lu, C.-T. Wang, C. Santos, A. Rodriguez-Carmona, M. Perez Fontan, B. Schaefer, S. Macher-Goeppinger, A. Bayazit, P. Sallay, S. Testa, S. Holland-Cunz, U. Querfeld, B. A. Warady, F. Schaefer, C. P. Schmitt, I. Guney, K. Turkmen, R. Yazici, S. Aslan, L. Altintepe, M. Yeksan, I. Kocyigit, M. Sipahioglu, O. Orscelik, A. Unal, A. Celik, S. Abbas, F. Zhu, B. Tokgoz, A. Dogan, O. Oymak, P. Kotanko, N. Levin, M. C. Sanchez-Gonzalez, M. L. Gonzalez-Casaus, E. Gonzalez-Parra, M. Albalate, V. Lorenzo, V. Torregrosa, E. Fernandez, C. de la Piedra, M. Rodriguez, M. Zeiler, T. Monteburini, R. M. Agostinelli, R. Marinelli, S. Santarelli, F. Bermond, C. Bagnis, C. Marcuccio, G. Soragna, M. Bruno, C. Vitale, M. Marangella, F. Martino, E. Scalzotto, M. P. Rodighiero, C. Crepaldi, C. Ronco, S. Seferi, M. Rroji, E. Likaj, M. Barbullushi, N. Thereska, E. J. Kim, J. H. Han, H. M. Koo, F. M. Doh, C. H. Kim, K. I. Ko, M. J. Lee, H. J. Oh, S. H. Han, T.-H. Yoo, K. H. Choi, S.-W. Kang, S. Uzun, S. Karadag, M. Yegen, M. Gursu, S. Ozturk, Z. Aydin, A. Sumnu, E. Cebeci, E. Atalay, R. Kazancioglu, D. Alscher, P. Fritz, J. Latus, M. Kimmel, D. Biegger, M. Lindenmeyer, C. D. Cohen, R. P. Wuthrich, S. Segerer, Y. K. Kim, H. W. Kim, H. C. Song, E. J. Choi, C. W. Yang, A. Matsuda, Y. Tayama, T. Ogawa, M. Iwanaga, S. Okazaki, M. Hatano, T. Kiba, T. Shimizu, H. Hasegawa, T. Mitarai, M. Dratwa, F. Collart, C. Verger, K. Takayanagi, T. Iwashita, C. Noiri, M. Inamura, S. Nakamura, H. Kato, M. H. Sipahioglu, F. Elmali, X. Zhang, J. Ma, A. Giuliani, L. Blanca-Martos, A. Nayak Karopadi, G. Mason, M. T. Santos, I. Fonseca, O. Santos, M. J. Rocha, M. J. Carvalho, A. Cabrita, A. Rodrigues, L. Scabbia, A. Domenici, F. Apponi, M. Tayefeh Jafari, F. Sivo, C. Falcone, G. Punzo, P. Mene, T. Yildirim, R. Yilmaz, A. Azak, M. Altindal, E. Turkmen, B. Altun, M. Duranay, Y. Erdem, M. Buyukbakkal, B. Eser, O. Yayar, Z. Ercan, A. Kali, B. Erdogan, A. Haspulat, O. Merhametsiz, G. Ulusal-Okyay, S. I. Akdag, M. D. Ayli, A. Pietrzycka, P. Miarka, E. Chowaniec, W. Sulowicz, M. Lutwin, M. Gaska, and A. Paciorek
- Subjects
Transplantation ,medicine.medical_specialty ,Nephrology ,business.industry ,medicine.medical_treatment ,Urology ,Medicine ,business ,Peritoneal dialysis - Published
- 2013
10. Epidemiology and outcome research in CKD 5D
- Author
-
L. Coentrao, C. Ribeiro, C. Santos-Araujo, R. Neto, M. Pestana, W. Kleophas, A. Karaboyas, Y. LI, J. Bommer, R. Pisoni, B. Robinson, F. Port, G. Celik, B. Burcak Annagur, M. Yilmaz, T. Demir, F. Kara, K. Trigka, P. Dousdampanis, N. Vaitsis, S. Aggelakou-Vaitsi, K. Turkmen, I. Guney, F. Turgut, L. Altintepe, H. Z. Tonbul, E. Abdel-Rahman, P. Sclauzero, G. Galli, G. Barbati, M. Carraro, G. O. Panzetta, M. Van Diepen, M. Schroijen, O. Dekkers, F. Dekker, A. Sikole, G. Severova- Andreevska, L. Trajceska, S. Gelev, V. Amitov, S. Pavleska- Kuzmanovska, H. Rayner, R. Vanholder, M. Hecking, B. Jung, M. Leung, F. Huynh, T. Chung, S. Marchuk, M. Kiaii, L. Er, R. Werb, C. Chan-Yan, M. Beaulieu, P. Malindretos, P. Makri, G. Zagkotsis, G. Koutroumbas, G. Loukas, E. Nikolaou, M. Pavlou, E. Gourgoulianni, M. Paparizou, M. Markou, E. Syrgani, C. Syrganis, J. Raimann, L. A. Usvyat, V. Bhalani, N. W. Levin, P. Kotanko, X. Huang, P. Stenvinkel, A. R. Qureshi, U. Riserus, T. Cederholm, P. Barany, O. Heimburger, B. Lindholm, J. J. Carrero, J. H. Chang, J. Y. Sung, J. Y. Jung, H. H. Lee, W. Chung, S. Kim, J. S. Han, K. Y. Na, A. Fragoso, A. Pinho, A. Malho, A. P. Silva, E. Morgado, P. Leao Neves, N. Joki, Y. Tanaka, M. Iwasaki, S. Kubo, T. Hayashi, Y. Takahashi, K. Hirahata, Y. Imamura, H. Hase, C. Castledine, J. Gilg, C. Rogers, Y. Ben-Shlomo, F. Caskey, J. S. Sandhu, G. S. Bajwa, S. Kansal, J. Sandhu, A. Jayanti, M. Nikam, L. Ebah, A. Summers, S. Mitra, J. Agar, A. Perkins, R. Simmonds, A. Tjipto, S. Amet, V. Launay-Vacher, M. Laville, A. Tricotel, C. Frances, B. Stengel, J.-Y. Gauvrit, N. Grenier, G. Reinhardt, O. Clement, N. Janus, L. Rouillon, G. Choukroun, G. Deray, A. Bernasconi, R. Waisman, A. P. Montoya, A. A. Liste, R. Hermes, G. Muguerza, R. Heguilen, E. L. Iliescu, V. Martina, M. A. Rizzo, P. Magenta, L. Lubatti, G. Rombola, M. Gallieni, C. Loirat, H. Mellerio, M. Labeguerie, B. Andriss, E. Savoye, M. Lassale, C. Jacquelinet, C. Alberti, Y. Aggarwal, J. Baharani, S. Tabrizian, S. Ossareh, M. Zebarjadi, P. Azevedo, F. Travassos, I. Frade, M. Almeida, J. Queiros, F. Silva, A. Cabrita, R. Rodrigues, C. Couchoud, J. Kitty, S. Benedicte, C. Fergus, C. Cecile, B. Sahar, V. Emmanuel, J. Christian, E. Rene, H. Barahimi, M. Mahdavi-Mazdeh, M. Nafar, M. Petruzzi, M. De Benedittis, M. Sciancalepore, L. Gargano, P. Natale, M. C. Vecchio, V. Saglimbene, F. Pellegrini, G. Gentile, P. Stroumza, L. Frantzen, M. Leal, M. Torok, A. Bednarek, J. Dulawa, E. Celia, R. Gelfman, J. Hegbrant, C. Wollheim, S. Palmer, D. W. Johnson, P. J. Ford, J. C. Craig, G. F. Strippoli, M. Ruospo, B. El Hayek, B. Hayek, E. Baamonde, E. Bosch, J. I. Ramirez, G. Perez, A. Ramirez, A. Toledo, M. M. Lago, C. Garcia-Canton, M. D. Checa, B. Canaud, B. Lantz, A. Granger-Vallee, P. Lertdumrongluk, N. Molinari, J. Ethier, M. Jadoul, B. Gillespie, C. Bond, S. Wang, T. Alfieri, P. Braunhofer, B. Newsome, M. Wang, B. Bieber, M. Guidinger, L. Zuo, X. Yu, X. Yang, J. Qian, N. Chen, J. Albert, Y. Yan, S. Ramirez, M. Beresan, A. Lapidus, M. Canteli, A. Tong, B. Manns, J. Craig, G. Strippoli, M. Mortazavi, B. Vahdatpour, S. Shahidi, A. Ghasempour, D. Taheri, S. Dolatkhah, A. Emami Naieni, M. Ghassami, M. Khan, K. Abdulnabi, P. Pai, M. Vecchio, M. A. Muqueet, M. J. Hasan, M. A. Kashem, P. K. Dutta, F. X. Liu, L. Noe, T. Quock, N. Neil, G. Inglese, M. Motamed Najjar, B. Bahmani, A. Shafiabadi, J. Helve, M. Haapio, P.-H. Groop, C. Gronhagen-Riska, P. Finne, R. Sund, M. Cai, S. Baweja, A. Clements, A. Kent, R. Reilly, N. Taylor, S. Holt, L. Mcmahon, M. Carter, F. M. Van der Sande, J. Kooman, R. Malhotra, G. Ouellet, E. L. Penne, S. Thijssen, M. Etter, A. Tashman, A. Guinsburg, A. Grassmann, C. Barth, C. Marelli, D. Marcelli, G. Von Gersdorff, I. Bayh, L. Scatizzi, M. Lam, M. Schaller, T. Toffelmire, Y. Wang, P. Sheppard, L. Neri, V. A. Andreucci, L. A. Rocca-Rey, S. V. Bertoli, D. Brancaccio, G. De Berardis, G. Lucisano, D. Johnson, A. Nicolucci, C. Bonifati, S. D. Navaneethan, V. Montinaro, M. Zsom, A. Bednarek-Skublewska, G. Graziano, J. N. Ferrari, A. Santoro, A. Zucchelli, G. Triolo, S. Maffei, S. De Cosmo, V. M. Manfreda, L. Juillard, A. Rousset, F. Butel, S. Girardot-Seguin, T. Hannedouche, M. Isnard, Y. Berland, P. Vanhille, J.-P. Ortiz, G. Janin, P. Nicoud, M. Touam, E. Bruce, B. Grace, P. Clayton, A. Cass, S. Mcdonald, Y. Furumatsu, T. Kitamura, N. Fujii, S. Ogata, H. Nakamoto, K. Iseki, Y. Tsubakihara, C.-C. Chien, J.-J. Wang, J.-C. Hwang, H.-Y. Wang, W.-C. Kan, N. Kuster, L. Patrier, A.-S. Bargnoux, M. Morena, A.-M. Dupuy, S. Badiou, J.-P. Cristol, J.-M. Desmet, V. Fernandes, F. Collart, N. Spinogatti, J.-M. Pochet, M. Dratwa, E. Goffin, J. Nortier, D. S. Zilisteanu, M. Voiculescu, E. Rusu, C. Achim, R. Bobeica, S. Balanica, T. Atasie, S. Florence, S. Anne-Marie, L. Michel, C. Cyrille, A. Strakosha, N. Pasko, S. Kodra, N. Thereska, A. Lowney, E. Lowney, R. Grant, M. Murphy, L. Casserly, T. O' Brien, W. D. Plant, J. Radic, D. Ljutic, V. Kovacic, M. Radic, K. Dodig-Curkovic, M. Sain, I. Jelicic, T. Hamano, C. Nakano, S. Yonemoto, A. Okuno, M. Katayama, Y. Isaka, M. Nordio, A. Limido, M. Postorino, M. Nichelatti, M. Khil, I. Dudar, V. Khil, I. Shifris, M. Momtaz, A. R. Soliman, M. I. El Lawindi, P. Dzekova-Vidimliski, S. Pavleska-Kuzmanovska, I. Nikolov, G. Selim, T. Shoji, R. Kakiya, N. Tatsumi-Shimomura, Y. Tsujimoto, T. Tabata, H. Shima, K. Mori, S. Fukumoto, H. Tahara, H. Koyama, M. Emoto, E. Ishimura, Y. Nishizawa, and M. Inaba
- Subjects
Transplantation ,medicine.medical_specialty ,Nephrology ,business.industry ,Epidemiology ,Medicine ,business ,Intensive care medicine ,Outcome (game theory) - Published
- 2012
11. New determination of the mass of Pallas
- Author
-
E. Goffin
- Subjects
Physics ,Space and Planetary Science ,Planet ,Asteroid ,Astronomy ,Terrestrial planet ,Astronomy and Astrophysics ,Protoplanet ,Planetary mass ,Jupiter mass ,Minor planet ,Astrobiology ,Planetary migration - Abstract
Until very recently, the mass of minor planet 2 Pallas had been determined from its gravitational effects on only 1 Ceres and the planet Mars. An independent confirmation was therefore highly desirable. This paper presents individual mass determinations based on close encounters with 16 other minor planets, as well as a simultaneous solution using all objects. The resulting value for the mass of Pallas, , essentially confirms the result from Ceres alone.
- Published
- 2001
12. [Focusing on peritoneal dialysis adequacy]
- Author
-
Belkacem, Issad, Pierre-Yves, Durand, Pascale, Siohan, Eric, Goffin, Joëlle, Cridlig, Guillaume, Jean, Jean-Philippe, Ryckelynck, W, Arkouche, J-P, Bourdenx, J, Cridlig, B, Dallaporta, H, Fessy, M, Fischbach, P, Giaime, E, Goffin, B, Issad, G, Jean, D, Joly, L, Mercadal, J-M, Poux, J-P, Ryckelynck, P, Siohan, M, Souid, D, Toledano, C, Verger, P, Vigeral, and M, Uzan
- Subjects
Chronic Kidney Disease-Mineral and Bone Disorder ,Glucose ,Metabolic Clearance Rate ,Malnutrition ,Humans ,Water-Electrolyte Balance ,Kidney ,Peritoneal Dialysis ,Glomerular Filtration Rate ,Phosphates - Abstract
The optimal method to assess the adequacy of peritoneal dialysis therapies is controversial. Today, the adequacy must not be considered as a number or a concept assessed only by two parameters (total KT/V urea and total solute clearance) but defined by many more items. In the absence of data, based on theoretical considerations, the reanalysis of the CANUSA study showed that renal kidney function, rather than peritoneal clearance, was associated with improved survival. Residual renal function is considered as a major predictor factor of cardiovascular mortality. Results of this reanalysis were supported by the adequacy data in ADEMEX, EAPOS and ANZDATA studies. Therefore, clinical assessment plays a major role in PD adequacy. The management of fluid balance, the regular monitoring of malnutrition, the control of mineral metabolism and particularly the glucose load, considered as the "corner-stone" of the system, are the main points to be considered in the adequacy of PD patients. The essential goal is to minimize glucose load by glucose-sparing strategies in order to reduce the neoangiogenesis of the peritoneal membrane.
- Published
- 2013
13. Technetium-labelled autologous lymphocytes
- Author
-
C B Sampson and E Goffin
- Subjects
business.industry ,Lymphocyte ,chemistry.chemical_element ,General Medicine ,Technetium ,In vitro ,Low volume ,chemistry.chemical_compound ,medicine.anatomical_structure ,Clinical work ,chemistry ,Labelling ,medicine ,Technetium Tc 99m Exametazime ,Radiology, Nuclear Medicine and imaging ,Trypan blue ,Nuclear medicine ,business - Abstract
Little clinical work has been performed using technetium-labelled lymphocytes due to the difficulty of effecting an imaging dose of technetium on the small number of lymphocytes available. We have successfully labelled lymphocytes using a high concentration and low volume of 99Tcm-exametazime. In eight readings from three patients and two volunteers, the labelling efficiency was 27% (4 S.D.). The radiolabel was stable in plasma in vitro up to 4 h. Viability of the lymphocytes as determined by trypan blue exclusion was greater than 95%.
- Published
- 1991
14. Book Reviews
- Author
-
L. Delaunois, E. Goffin, and M. Jadoul
- Subjects
General Medicine - Published
- 1995
15. Book Reviews
- Author
-
E. Goffin, J.Y. Reginster, A. Kint, D. Schrijvers, and N. Lameire
- Subjects
General Medicine - Published
- 1994
16. Acute necrotico-hemorrhagic pancreatitis after famciclovir prescription
- Author
-
E, Goffin, Y, Horsmans, Y, Pirson, C, Cornu, A, Geubel, and C, van Ypersele De Strihou
- Subjects
Male ,Hepatitis B virus ,Famciclovir ,Alanine Transaminase ,Bilirubin ,Hemorrhage ,Lipase ,Middle Aged ,Hepatitis B ,Antiviral Agents ,Kidney Transplantation ,Leukocyte Count ,Necrosis ,Fatal Outcome ,Postoperative Complications ,Pancreatitis ,Acute Disease ,Amylases ,DNA, Viral ,Cyclosporine ,Humans ,Prodrugs ,2-Aminopurine - Published
- 1995
17. Acute renal failure due to naftidrofuryl oxalate Praxilène overdose in a kidney transplant recipient
- Author
-
C, Cuvelier, E, Goffin, J P, Cosyns, N, Claeys, J P, Squifflet, Y, Pirson, and C V, de Strihou
- Subjects
Adult ,Peripheral Vascular Diseases ,Calcium Oxalate ,Vasodilator Agents ,Humans ,Nafronyl ,Female ,Acute Kidney Injury ,Drug Overdose ,Crystallization ,Infusions, Intravenous ,Kidney Transplantation - Published
- 1995
18. Rheological response of neutrophils to different types of stimulation
- Author
-
R. Hatton, C. M. Lockwood, E. Goffin, William MacNee, Ellen M Drost, Gerard B. Nash, and S. M. Buttrum
- Subjects
Adult ,Physiology ,Cytochalasin B ,Neutrophils ,Cell ,Phenylalanine ,Stimulation ,Shape formation ,Neutrophil Activation ,Antibodies, Antineutrophil Cytoplasmic ,Leukocyte Count ,Rheology ,Physiology (medical) ,Smoke ,medicine ,Humans ,Autoantibodies ,Chemistry ,Pipette ,Chemotaxis ,In vitro ,N-Formylmethionine Leucyl-Phenylalanine ,medicine.anatomical_structure ,Immunoglobulin G ,Immunology ,Biophysics - Abstract
The potential for neutrophils to obstruct microvessels was evaluated by measuring transit of individual neutrophils through 8-microns pores in an automated cell transit analyzer (CTA) or into micropipettes (4–8 microns ID). Stimulation in vitro by the chemotactic agent N-formyl-methionyl-leucyl-phenylalanine. (fMLP), cigarette smoke, or purified antineutrophil cytoplasm antibodies greatly increased flow resistance, but the response varied in its dependence on time and pore diameter. Cigarette smoke or fMLP caused rapid loss of cellular deformability, although observations were complicated by changes in cell shape: progressive bipolar shape formation (after treatment with fMLP) could facilitate entry into larger pores (approximately 8 microns), whereas blebs induced by cigarette smoke caused bridging of these pores with cell immobilization. These processes led to an underestimation of the changes in deformability by the CTA. Neutrophils responded slowly to the antineutrophil cytoplasm antibodies (approximately 30 min), with a greater increase in flow resistance evaluated by a micro-pipette (4–6 microns ID) than by the CTA. We conclude that the effect of neutrophil stimulation on flow through capillary-sized vessels is potentially great (with resistance typically increased 10-fold or even complete blockage) but may depend on the vascular and cellular geometry and may be local or disseminated, depending on the rate of the rheological response.
- Published
- 1994
19. The interaction between clarithromycin and cyclosporine in kidney transplant recipients
- Author
-
S L, Ferrari, E, Goffin, M, Mourad, P, Wallemacq, J P, Squifflet, and Y, Pirson
- Subjects
Adult ,Graft Rejection ,Male ,Clarithromycin ,Creatinine ,Cyclosporine ,Humans ,Drug Interactions ,Middle Aged ,Kidney Transplantation - Published
- 1994
20. Spurious elevation of serum thyrotropin (TSH) after OKT3 administration
- Author
-
E, Goffin, M, Lambert, P, De Nayer, J M, Saint-Remy, Y, Pirson, and C, van Ypersele de Strihou
- Subjects
Graft Rejection ,Male ,Adolescent ,Hypothyroidism ,Humans ,Thyrotropin ,Antibodies, Heterophile ,False Positive Reactions ,Kidney Transplantation ,Antibodies, Anti-Idiotypic ,Muromonab-CD3 - Published
- 1994
21. Reply
- Author
-
M. Jadoul, P. Nguyen, S. Henrard, E. Coche, E. Goffin, and O. Devuyst
- Subjects
Transplantation ,Nephrology - Published
- 2011
22. Two kidney-transplant women with therapy-resistant hypertension: diagnostic error of a renal artery stenosis.
- Author
-
G. Clerbaux, P. Goffette, Y. Pirson, and E. Goffin
- Published
- 2003
- Full Text
- View/download PDF
23. In vitro repair potential of articular cartilage: proteoglycan metabolism in the different areas of the femoral condyles in human cartilage explants
- Author
-
F P, Luyten, G, Verbruggen, E M, Veys, E, Goffin, and H, De Pypere
- Subjects
Cartilage, Articular ,Culture Techniques ,Humans ,Proteoglycans ,Tissue Distribution ,Trypsin ,Femur ,Culture Media - Abstract
We tested the hypothesis that metabolism of individual cartilage samples, such as those which might be taken at arthroscopy, could reflect the overall intrinsic reparative response of the cartilaginous tissue of that joint. Full thickness samples of articular cartilage, removed from the anteromedial, anterolateral and posterolateral areas of the femoral condyles of 2 normal knees, were placed in tissue culture separately. The incorporation of 14C-glucosamine into matrix molecules, especially proteoglycan, was measured. Three slices of each area were removed after one, 3 or 6 weeks of in vitro culture. The extracted matrix molecules and the media were analyzed and the relative amount of radioactive proteoglycan and proteoglycan aggregates, as well as the total amount of radiolabelled proteoglycan/mg dry weight, were calculated. A progressive increase in these variables during the culture period was demonstrated, suggesting an attempt at repair of the articular cartilage in this in vitro condition. No differences in the incorporation dynamics were found between the anteromedial, anterolateral and posterolateral areas of both subjects.
- Published
- 1987
24. ChemInform Abstract: SYNTHESIS OF YNAMIDES- N-ACETYLENIC AMIDES, UREAS, AND CARBAMATES, VIA THEIR HALOALKENYL DERIVATIVES, FROM SECONDARY AMIDES AND PHOSGENE OR PHOSGENIMINIUM SALTS
- Author
-
Y. Legrand, H. G. Viehe, and E. Goffin
- Subjects
chemistry.chemical_compound ,Chemistry ,Organic chemistry ,General Medicine ,Phosgene - Published
- 1977
25. Die Entdeckung eines neuen Asteroiden (1988BJ) vom 'Hungaria'-Typ
- Author
-
E. W. Elst and E. Goffin
- Subjects
Physics ,Orbital elements ,Solar System ,Space and Planetary Science ,Asteroid ,Observatory ,Magnitude (astronomy) ,Astronomy and Astrophysics ,Astrophysics ,Orbit (control theory) - Abstract
Wahrend eines Asteroiden-Beobachtungsprogramms in Haute Provence (Frankreich) wurde am 22. Januar 1988 ein Asteroid 17. Grose entdeckt (Elst 1988). Weitere Beobachtungen an der Europaischen Sudsternwarte (ESO) und eine vorlaufige Bahnbestimmung ergaben, das der Asteroid zur “Hungaria”-Familie (Resonanzgruppe) gehort. During an observational program of asteroids at the observatory of Haute Provence (France) an asteroid of 17th magnitude was discovered on 22nd January 1988 (Elst 1988). Further observations at the European Southern Observatory (ESO) and a preliminary determination of an orbit revealed that it belongs to the “Hungaria” family.
- Published
- 1989
26. ERRATA: ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment.
- Author
-
P. K., Li, C. C., Szeto, B., Piraino, J., de Arteaga, S., Fan, A. E., Figueiredo, D. N., Fish, E., Goffin, Y. L., Kim, W., Salzer, D. G., Struijk, I., Teitelbaum, and D. W., Johnson
- Published
- 2018
- Full Text
- View/download PDF
27. Ticagrelor alters the membrane of Staphylococcus aureus and enhances the activity of vancomycin and daptomycin without eliciting cross-resistance.
- Author
-
Leeten K, Jacques N, Esquembre LA, Schneider DC, Straetener J, Henriksen C, Musumeci L, Putters F, Melo S, Sánchez-López E, Giera M, Penoy N, Piel G, Verlaine O, Amoroso A, Joris B, Slavetinsky CJ, Goffin E, Pirotte B, Frees D, Brötz-Oesterhelt H, Lancellotti P, and Oury C
- Abstract
Infections with multidrug-resistant bacteria pose a major healthcare problem which urges the need for novel treatment options. Besides its potent antiplatelet properties, ticagrelor has antibacterial activity against Gram-positive bacteria, including methicillin- and vancomycin-resistant Staphylococcus aureus (MRSA and VRSA). Several retrospective studies in cardiovascular patients support an antibacterial effect of this drug which is not related to its antiplatelet activity. We investigated the mechanism of action of ticagrelor in Staphylococcus aureus and model Bacillus subtilis, and assessed cross-resistance with two conventional anti-MRSA antibiotics, vancomycin and daptomycin. Bacillus subtilis bioreporter strains revealed ticagrelor-induced cell envelope-related stress responses. Sub-inhibitory drug concentrations caused membrane depolarization, impaired positioning of both the peripheral membrane protein MinD and the peptidoglycan precursor lipid II, and it affected cell shape. At the MIC, ticagrelor destroyed membrane integrity, indicated by the influx of membrane impermeable dyes, and lipid aggregate formation. Whole-genome sequencing of in vitro -generated ticagrelor-resistant MRSA clones revealed mutations in genes encoding ClpP, ClpX, and YjbH. Lipidomic analysis of resistant clones displayed changes in levels of the most abundant lipids of the Staphylococcus aureus membrane, for example, cardiolipins, phosphatidylglycerols, and diacylglycerols. Exogeneous cardiolipin, phosphatidylglycerol, or diacylglycerol antagonized the antibacterial properties of ticagrelor. Ticagrelor enhanced MRSA growth inhibition and killing by vancomycin and daptomycin in both exponential and stationary phases. Finally, no cross-resistance was observed between ticagrelor and daptomycin, or vancomycin. Our study demonstrates that ticagrelor targets multiple lipids in the cytoplasmic membrane of Gram-positive bacteria, thereby retaining activity against multidrug-resistant staphylococci including daptomycin- and vancomycin-resistant strains.IMPORTANCEInfections with multidrug-resistant bacteria pose a major healthcare problem with an urgent need for novel treatment options. The antiplatelet drug ticagrelor possesses antibacterial activity against Gram-positive bacteria including methicillin-resistant and vancomycin-resistant Staphylococcus aureus strains. We report a unique, dose-dependent, antibacterial mechanism of action of ticagrelor, which alters the properties and integrity of the bacterial cytoplasmic membrane. Ticagrelor retains activity against multidrug-resistant staphylococci, including isolates carrying the most common in vivo selected daptomycin resistance mutations and vancomycin-intermediate Staphylococcus aureus . Our data support the use of ticagrelor as adjunct therapy against multidrug-resistant strains. Because of the presence of multiple non-protein targets of this drug within the bacterial membrane, resistance development is expected to be slow. All these findings corroborate the accumulating observational clinical evidence for a beneficial anti-bacterial effect of ticagrelor in cardiovascular patients in need of such treatment.
- Published
- 2024
- Full Text
- View/download PDF
28. Living Donor Exchange Program in Kidney Transplantation: An Underexploited Organ Resource.
- Author
-
Kanaan N, Mourad M, and Goffin E
- Abstract
Competing Interests: The authors declare no funding or conflicts of interest.
- Published
- 2024
- Full Text
- View/download PDF
29. Bridging the Gap Between CKD Management Paradigms in Transplant and Nontransplant Settings: Published Evidence, Challenges, and Perspectives.
- Author
-
Dufour I, Van Regemorter E, Kanaan N, Buemi A, Darius T, Mourad M, Goffin E, Jadoul M, Devresse A, and Gillion V
- Abstract
Kidney transplantation (KT) is the best treatment for patients with kidney failure, associated with improved survival and quality of life compared with maintenance dialysis. However, despite constant improvements in the assessment and management of the alloimmune response, KT patients frequently demonstrate a reduced estimated glomerular filtration rate. Therefore, the usual complications of chronic kidney disease (CKD), such as anemia, hypertension, metabolic acidosis, hyperkalemia, or persistent secondary hyperparathyroidism, are highly prevalent after KT. However, their underlying mechanisms are different in the transplant setting (compared with the nontransplanted CKD population), and management recommendations are based on relatively poor-quality data. In recent years, new therapies have emerged, significantly improving kidney and cardiovascular outcomes of non-KT patients with CKD. Whether those new drugs could improve the outcomes of KT patients has largely been under investigated so far. In this review, we will address the challenges of the management of a KT patient with a reduced estimated glomerular filtration rate, cover the published evidence, and highlight the critical knowledge gaps., Competing Interests: T.D. reports research support from the Fonds National de Recherche Scientifique – FNRS (F.R.S.-FNRS) as well as travel support from Organ Recovery Systems, Diegem, Belgium. E.G. reports research support from Baxter Healthcare, conference support from Baxter Healthcare, Fresenius, Nx Stage, Dirinco, and AstraZeneca; and consulting fees from Amgen, Astellas, AstraZeneca, Bayer, Baxter Healthcare, Fresenius, NxStage, and Dirinco. M.J. reports research support from AstraZeneca, speaker fees from AstraZeneca, Bayer, Boehringer-Ingelheim, and Menarini; consulting fees from Astellas, AstraZeneca, Bayer, Boehringer-Ingelheim, Cardiorenal, CSL Vifor, GlaxoSmithKline, Stada-Eurogenerics, and Vertex; and other: co-chair of Kidney Disease Improving Global Outcomes (KDIGO) since January 2019. A.D. reports consultancy fees from Alnylam and Merck. E.V.R. reports support from CSL Vifor and Pharmacosmos; speaker fees from Baxter Healthcare, Astellas, and Bayer; and consulting fees from Bayer. N.K. reports consulting fees from Hansa Biopharm. The other authors declare no conflicts of interest., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
30. Association Between Serum Phosphate Levels and Progression of Aortic Stenosis.
- Author
-
Candellier A, Diouf M, Bohbot Y, Bennis Y, Pasquet A, Goffin E, Hénaut L, Choukroun G, Vanoverschelde JL, and Tribouilloy C
- Published
- 2024
- Full Text
- View/download PDF
31. Valine aminoacyl-tRNA synthetase promotes therapy resistance in melanoma.
- Author
-
El-Hachem N, Leclercq M, Susaeta Ruiz M, Vanleyssem R, Shostak K, Körner PR, Capron C, Martin-Morales L, Roncarati P, Lavergne A, Blomme A, Turchetto S, Goffin E, Thandapani P, Tarassov I, Nguyen L, Pirotte B, Chariot A, Marine JC, Herfs M, Rapino F, Agami R, and Close P
- Subjects
- Animals, Humans, Mice, Amino Acyl-tRNA Synthetases metabolism, Amino Acyl-tRNA Synthetases genetics, Cell Line, Tumor, Gene Expression Regulation, Neoplastic, Protein Biosynthesis, Protein Kinase Inhibitors pharmacology, Valine metabolism, Valine genetics, Xenograft Model Antitumor Assays, Drug Resistance, Neoplasm genetics, Melanoma genetics, Melanoma pathology, Melanoma enzymology, Melanoma drug therapy, Melanoma metabolism
- Abstract
Transfer RNA dynamics contribute to cancer development through regulation of codon-specific messenger RNA translation. Specific aminoacyl-tRNA synthetases can either promote or suppress tumourigenesis. Here we show that valine aminoacyl-tRNA synthetase (VARS) is a key player in the codon-biased translation reprogramming induced by resistance to targeted (MAPK) therapy in melanoma. The proteome rewiring in patient-derived MAPK therapy-resistant melanoma is biased towards the usage of valine and coincides with the upregulation of valine cognate tRNAs and of VARS expression and activity. Strikingly, VARS knockdown re-sensitizes MAPK-therapy-resistant patient-derived melanoma in vitro and in vivo. Mechanistically, VARS regulates the messenger RNA translation of valine-enriched transcripts, among which hydroxyacyl-CoA dehydrogenase mRNA encodes for a key enzyme in fatty acid oxidation. Resistant melanoma cultures rely on fatty acid oxidation and hydroxyacyl-CoA dehydrogenase for their survival upon MAPK treatment. Together, our data demonstrate that VARS may represent an attractive therapeutic target for the treatment of therapy-resistant melanoma., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
32. Etelcalcetide use During Maintenance Hemodialysis and Incidence of Parathyroidectomy After Kidney Transplantation.
- Author
-
Delaey P, Devresse A, Morelle J, Faitatzidou D, Iriarte M, Kanaan N, Buemi A, Mourad M, Darius T, Goffin E, Jadoul M, and Labriola L
- Abstract
Introduction: Etelcalcetide is an i.v. calcimimetic agent, effectively reducing parathyroid hormone levels in patients on maintenance hemodialysis (HD). The clinical impact of discontinuing etelcalcetide at the time of kidney transplantation is unknown., Methods: We retrospectively reviewed all patients on HD meeting predefined criteria who received a kidney transplant at our institution between January 1, 2015, and December 12, 2022. The incidence of parathyroidectomy and the evolution of calcium, phosphate, and intact parathyroid hormone (iPTH) levels after transplantation was analyzed according to the type of calcimimetic treatment before transplantation (cinacalcet vs. etelcalcetide vs. none)., Results: Overall, 372 patients (aged 53 years; interquartile range [IQR]: 42-62 years) were included. At the time of transplantation, 35, 75, and 262 patients were under etelcalcetide, cinacalcet, or no calcimimetic, respectively. After 1064 (IQR: 367-1658) days, the incidences of parathyroidectomy in the etelcalcetide, cinacalcet, no calcimimetic groups were 29%, 12%, and 1%, respectively ( P < 0.001). Etelcalcetide was associated with an increased incidence of parathyroidectomy after adjustment for age, sex, and HD vintage (hazard ratio [HR]: 97.0, 95% confidence interval [CI]: 19.1-493.9, P < 0.001). The incidence of parathyroidectomy was related to etelcalcetide dosage (6/11 [54.6%] in patients with ≥ 10 mg vs. 4/24 [16.7%] in patients with < 10 mg, P = 0.02). Moreover, peak calcium levels were higher ( P < 0.001) and parathyroidectomy was performed earlier (median 80 vs. 480 days, P < 0.001) in the etelcalcetide compared with the cinacalcet group. Long-term graft function, graft loss, and mortality were similar., Conclusion: Etelcalcetide use during maintenance HD is associated with an increased incidence of early parathyroidectomy after transplantation compared to cinacalcet or no calcimimetic., (© 2024 International Society of Nephrology. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
33. How do successive vaccinations and SARS-CoV-2 infections impact humoral immunity dynamics: An 18-month longitudinal study.
- Author
-
Diep AN, Schyns J, Gourzones C, Goffin E, Papadopoulos I, Moges S, Minner F, Ek O, Bonhomme G, Paridans M, Gillain N, Husson E, Garigliany M, Darcis G, Saegerman C, Desmecht D, Guillaume M, A F D, Bureau F, and Gillet L
- Subjects
- Humans, Immunity, Humoral, Longitudinal Studies, SARS-CoV-2, Antibodies, Viral, Vaccination, COVID-19 prevention & control
- Abstract
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
- Published
- 2024
- Full Text
- View/download PDF
34. Exploring thienothiadiazine dioxides as isosteric analogues of benzo- and pyridothiadiazine dioxides in the search of new AMPA and kainate receptor positive allosteric modulators.
- Author
-
Francotte P, Bay Y, Goffin E, Colson T, Lesenfants C, Dorosz J, Laulumaa S, Fraikin P, de Tullio P, Beaufour C, Botez I, Pickering DS, Frydenvang K, Danober L, Kristensen AS, Kastrup JS, and Pirotte B
- Subjects
- Mice, Animals, alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid pharmacology, Receptors, Kainic Acid metabolism, Structure-Activity Relationship, Allosteric Regulation, Receptors, AMPA metabolism, Thiadiazines chemistry
- Abstract
The synthesis and biological evaluation on AMPA and kainate receptors of new examples of 3,4-dihydro-2H-1,2,4-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxides is described. The introduction of a cyclopropyl chain instead of an ethyl chain at the 4-position of the thiadiazine ring was found to dramatically improve the potentiator activity on AMPA receptors, with compound 32 (BPAM395) expressing in vitro activity on AMPARs (EC2x = 0.24 μM) close to that of the reference 4-cyclopropyl-substituted benzothiadiazine dioxide 10 (BPAM344). Interestingly, the 4-allyl-substituted thienothiadiazine dioxide 27 (BPAM307) emerged as the most promising compound on kainate receptors being a more effective potentiator than the 4-cyclopropyl-substituted thienothiadiazine dioxide 32 and supporting the view that the 4-allyl substitution of the thiadiazine ring could be more favorable than the 4-cyclopropyl substitution to induce marked activity on kainate receptors versus AMPA receptors. The thieno-analogue 36 (BPAM279) of the clinically tested S18986 (11) was selected for in vivo evaluation in mice as a cognitive enhancer due to a safer profile than 32 after massive per os drug administration. Compound 36 was found to increase the cognition performance in mice at low doses (1 mg/kg) per os suggesting that the compound was well absorbed after oral administration and able to reach the central nervous system. Finally, compound 32 was selected for co-crystallization with the GluA2-LBD (L504Y,N775S) and glutamate to examine the binding mode of thienothiadiazine dioxides within the allosteric binding site of the AMPA receptor. At the allosteric site, this compound established similar interactions as the previously reported BTD-type AMPA receptor modulators., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Pirotte Bernard reports financial support was provided by Servier Laboratories Suresnes. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Elsevier Masson SAS. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
35. Impact of thrice-weekly cotrimoxazole prophylaxis on creatinine and potassium plasma levels in kidney transplant recipients.
- Author
-
Ardhe A, Devresse A, Crott R, De Meyer M, Mourad M, Goffin E, Kanaan N, and Jadoul M
- Subjects
- Humans, Creatinine, Retrospective Studies, Potassium, Transplant Recipients, Trimethoprim, Sulfamethoxazole Drug Combination therapeutic use, Kidney Transplantation adverse effects
- Abstract
Introduction: Cotrimoxazole (CTX) 800/160 mg daily or thrice-weekly is recommended as prophylaxis of Pneumocystis jirovecii pneumonia in kidney transplant recipients. Cotrimoxazole 800/160 daily elevates plasma creatinine and potassium levels but whether the thrice-weekly regimen does so is unknown., Methods: Medical records of 225 kidney transplant recipients at Cliniques Universitaires Saint-Luc were analyzed retrospectively. All received thrice-weekly CTX 800/160 for 6 months after transplantation. Monthly laboratory results, co-medications, and tacrolimus trough levels were compared. Standard statistical tests were used., Results: One month after CTX stop, creatinine level decreased by 0.11 mg/dl (8%, p = 0.029). This contrasts with its stability in previous and subsequent months. No co-medication change accounted for this decrease. The decrease averaged 0.17 mg/dl (p < 0.01) in the highest initial creatinine tertile. The higher the initial creatinine level, the greater the decrease after CTX stop (p < 0.001), and urea levels remained stable after CTX stop. Potassium levels decreased by 0.09 mmol/L (p = 0.021) one month after CTX stop, and decreased by 0.23 mmol/L (p < 0.01) in the highest initial potassium level tertile., Conclusions: Our study pinpoints the impact of CTX 800/160 thrice-weekly on creatinine and potassium levels in kidney transplant recipients. This should be considered when interpreting the evolution of plasma creatinine over time, especially in patients with graft dysfunction. Thus, creatinine levels of cohorts with 6 months versus lifelong CTX require different interpretations., (© 2023. The Author(s) under exclusive licence to Italian Society of Nephrology.)
- Published
- 2023
- Full Text
- View/download PDF
36. Chronic kidney disease is a key risk factor for aortic stenosis progression.
- Author
-
Candellier A, Bohbot Y, Pasquet A, Diouf M, Vermes E, Goffin E, Gun M, Peugnet F, Hénaut L, Rusinaru D, Mentaverri R, Kamel S, Choukroun G, Vanoverschelde JL, and Tribouilloy C
- Subjects
- Humans, Stroke Volume, Retrospective Studies, Cross-Sectional Studies, Renal Dialysis, Ventricular Function, Left, Aortic Valve surgery, Risk Factors, Glomerular Filtration Rate, Disease Progression, Renal Insufficiency, Chronic complications, Renal Insufficiency, Chronic therapy, Aortic Valve Stenosis complications, Renal Insufficiency complications
- Abstract
Background: Rapid progression of aortic stenosis (AS) has been observed in patients undergoing dialysis, but existing cross-sectional evidence is contradictory in non-dialysis-dependent chronic kidney disease (CKD). The present study sought to evaluate whether CKD is associated with the progression of AS over time in a large cohort of patients with AS., Methods: We retrospectively studied all consecutive patients diagnosed with AS [peak aortic jet velocity (Vmax) ≥2.5 m/s] and left ventricular ejection fraction ≥50% in the echocardiography laboratories of two tertiary centers between 2000 and 2018. The estimated glomerular filtration rate (eGFR) (mL/min/1.73 m2) was calculated from serum creatinine values. Patients were divided into five CKD stages according to the baseline eGFR. Annual rates of change in the aortic valve area (AVA) were determined by a linear mixed-effects model., Results: Among the 647 patients included, 261 (40%) had CKD. After a median follow-up of 2.9 (interquartile range 1.8-4.8) years, the mean overall rate of change in AVA was -0.077 (95% confidence interval -0.082; -0.073) cm2/year. There was an inverse relationship between the progression rate and kidney function. The more severe the CKD stage, the greater the AVA narrowing (P < .001). By multivariable linear regression analysis, the eGFR was also negatively associated (P < .001) with AS progression. An eGFR strata below 45 mL/min/1.73 m2 was associated with higher odds of rapid progression of AS than normal kidney function. During the clinical follow-up, event-free survival (patients free of aortic valve replacement or death) decreased as CKD progressed. Rapid progression of AS in patients with kidney dysfunction was associated with worse outcomes., Conclusions: Patients with CKD exhibit more rapid progression of AS over time and require close monitoring. The link between kidney dysfunction and rapid progression of AS is still unknown and requires further research., (© The Author(s) 2023. Published by Oxford University Press on behalf of the ERA.)
- Published
- 2023
- Full Text
- View/download PDF
37. A Single Oral Immunization with a Replication-Competent Adenovirus-Vectored Vaccine Protects Mice from Influenza Respiratory Infection.
- Author
-
Goffin E, Du X, Hemmi S, Machiels B, and Gillet L
- Subjects
- Humans, Mice, Animals, Adenoviridae genetics, Antibodies, Viral, SARS-CoV-2, Immunization, Vaccination methods, Hemagglutinin Glycoproteins, Influenza Virus genetics, Adenovirus Vaccines, Influenza, Human prevention & control, COVID-19, Adenoviridae Infections, Influenza Vaccines
- Abstract
The development of effective and flexible vaccine platforms is a major public health challenge, especially in the context of influenza vaccines that have to be renewed every year. Adenoviruses (AdVs) are easy to produce and have a good safety and efficacy profile when administered orally, as demonstrated by the long-term use of oral AdV-4 and -7 vaccines in the U.S. military. These viruses therefore appear to be the ideal backbone for the development of oral replicating vector vaccines. However, research into these vaccines is limited by the ineffectiveness of human AdV replication in laboratory animals. The use of mouse AdV type 1 (MAV-1) in its natural host allows infection to be studied under replicating conditions. Here, we orally vaccinated mice with a MAV-1 vector expressing influenza hemagglutinin (HA) to assess the protection conferred against an intranasal challenge of influenza. We showed that a single oral immunization with this vaccine generates influenza-specific and -neutralizing antibodies and completely protects mice against clinical signs and viral replication, similar to traditional inactivated vaccines. IMPORTANCE Given the constant threat of pandemics and the need for annual vaccination against influenza and possibly emerging agents such as SARS-CoV-2, new types of vaccines that are easier to administer and therefore more widely accepted are a critical public health need. Here, using a relevant animal model, we have shown that replicative oral AdV vaccine vectors can help make vaccination against major respiratory diseases more available, better accepted, and therefore more effective. These results could be of major importance in the coming years in the fight against seasonal or emerging respiratory diseases such as COVID-19., Competing Interests: The authors declare no conflict of interest.
- Published
- 2023
- Full Text
- View/download PDF
38. Evaluation of a commercial interferon-γ release assay for the detection of SARS-CoV-2 T-cell response after vaccination.
- Author
-
Saad Albichr I, Mzougui S, Devresse A, Georgery H, Goffin E, Kanaan N, Yombi JC, Belkhir L, De Greef J, Scohy A, Rodriguez-Villalobos H, and Kabamba-Mukadi B
- Abstract
Objective: Evidence regarding the role of cellular immunity in protecting against COVID-19 is emerging. To better assess immune status, simple and robust assays measuring specific T-cell responses associated with humoral responses are needed. We aimed to evaluate the Quan-T-Cell SARS-CoV-2 test for measuring cellular immune responses in vaccinated healthy and immunosuppressed subjects., Methods: T-cell responses were assessed in healthy vaccinated and unvaccinated and unexposed healthcare workers to determine the sensitivity and specificity of the EUROIMMUN SARS-CoV-2 Quan-T-Cell IGRA test performed on vaccinated kidney transplant recipients (KTRs)., Results: The EUROIMMUN SARS-CoV-2 Quan-T-Cell IGRA test showed good sensitivity (87.2%) and specificity (92.3%) at the calculated 147 mIU/mL cutoff, with an 88.33% accuracy. In KTRs, specific cellular immunity was lower than the antibody response; however, those with a positive IGRA result produced as much IFN-γ as healthy individuals., Conclusions: The EUROIMMUN SARS-CoV-2 Quan-T-Cell IGRA test showed good sensitivity and specificity for the detection of specific T-cell responses against the SARS-CoV-2 spike protein. These results present an additional tool for better management of COVID-19, especially in vulnerable populations., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2023 The Authors.)
- Published
- 2023
- Full Text
- View/download PDF
39. Protective Effect of Ticagrelor Against Infective Endocarditis Induced by Virulent Staphylococcus aureus in Mice.
- Author
-
Oury C, Meyers S, Jacques N, Leeten K, Jiang Z, Musumeci L, Lox M, Debuisson M, Goffin E, Pirotte B, Delvenne P, Nchimi A, Hubert C, Heptia M, Hubert P, Kuijpers MJE, Vanassche T, Martinod K, Verhamme P, and Lancellotti P
- Abstract
In addition to its potent antiplatelet activity, ticagrelor possesses antibacterial properties against gram-positive bacteria. We wondered whether the typical clinical dosage of ticagrelor could prevent the development of infective endocarditis caused by highly virulent Staphylococcus aureus . Ticagrelor prevented vegetation formation in a mouse model of inflammation-induced endocarditis. The dosage achieved in patients under ticagrelor therapy altered bacterial toxin production and adherence on activated endothelial cells, thereby mitigating bacterial virulence. Besides the previously described bactericidal activity at high doses, ticagrelor at typical clinical doses possesses antivirulence activity against S aureus . Ticagrelor antiplatelet activity further interferes with the interplay between platelets and bacteria., Competing Interests: Dr Oury. is Research Director at the Belgium National Funds for Scientific Research (F.R.S.-FNRS). Research from the University of Liège (ULiège) is funded by F.R.S.-FNRS (grant number PDR T.0190.20) to Dr Oury; ULiège internal Fund grant numbers FSR-S-SS-19/18 and FSR-S-SS-21/41 to Dr Oury; and European Research Council Consolidator grant (grant number 647197) to Dr Lancellotti. Dr Meyers is a fellow of the Fonds Wetenschappelijk Onderzoek Vlaanderen (FWO) (1S77119N). Research from the group at the University of Leuven is funded by FWO research grants 1514518N and 1525319N, KU Leuven Internal Fund Starting Grant number STG/18/048 to Dr Martinod; FWO research project number G066021N to Drs Verhamme and Vanassche; and KU Leuven Internal Fund grant number C24M/20/056 to Drs Verhamme and Vanassche. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (© 2023 The Authors.)
- Published
- 2023
- Full Text
- View/download PDF
40. New insights in the development of positive allosteric modulators of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors belonging to 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxides: Introduction of (mono/difluoro)methyl groups at the 2-position of the thiadiazine ring.
- Author
-
Goffin E, Fraikin P, Abboud D, de Tullio P, Beaufour C, Botez I, Hanson J, Danober L, Francotte P, and Pirotte B
- Subjects
- Mice, Animals, alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid, Benzothiadiazines pharmacology, Benzothiadiazines chemistry, Thiazides, Allosteric Regulation, Receptors, AMPA metabolism, Thiadiazines pharmacology, Thiadiazines chemistry
- Abstract
Positive allosteric modulators of the AMPA receptors (AMPAR PAMs) have been proposed as new drugs for the management of various neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, attention deficit hyperactivity disorder, depression, and schizophrenia. The present study explored new AMPAR PAMs belonging to 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxides (BTDs) characterized by the presence of a short alkyl substituent at the 2-position of the heterocycle and by the presence or absence of a methyl group at the 3-position. The introduction of a monofluoromethyl or a difluoromethyl side chain at the 2-position instead of the methyl group was examined. 7-Chloro-4-cyclopropyl-2-fluoromethyl-3,4-dihydro-4H-1,2,4-benzothiadiazine 1,1-dioxide (15e) emerged as the most promising compound associating high in vitro potency on AMPA receptors, a favorable safety profile in vivo and a marked efficacy as a cognitive enhancer after oral administration in mice. Stability studies in aqueous medium suggested that 15e could be considered, at least in part, as a precursor of the corresponding 2-hydroxymethyl-substituted analogue and the known AMPAR modulator 7-chloro-4-cyclopropyl-3,4-dihydro-4H-1,2,4-benzothiadiazine 1,1-dioxide (3) devoid of an alkyl group at the 2-position., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Pirotte Bernard reports financial support was provided by Laboratoires Servier. Pirotte Bernard reports a relationship with Laboratoires Servier that includes: funding grants., (Copyright © 2023 Elsevier Masson SAS. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
41. Safety and efficiency of molnupiravir for COVID-19 patients with advanced chronic kidney disease.
- Author
-
Dufour I, Devresse A, Scohy A, Briquet C, Georgery H, Delaey P, Greef J, Goffin E, and Labriola L
- Published
- 2023
- Full Text
- View/download PDF
42. Quiz: A Case of Acute Intravascular Hemolysis During Dialysis: A Quiz.
- Author
-
Dufour I, Briol S, Van Regemorter E, Goffin E, and Devresse A
- Subjects
- Humans, Hemolysis, Renal Dialysis, Acute Kidney Injury
- Published
- 2023
- Full Text
- View/download PDF
43. Outcomes of COVID-19 in peritoneal dialysis patients: A report by the European Renal Association COVID-19 Database.
- Author
-
Abrahams AC, Noordzij M, Goffin E, Sanchez JE, Franssen CF, Vart P, Jager KJ, van Agteren M, Covic A, Mitra S, Basile C, Konings C, Hemmelder MH, Duivenvoorden R, Hilbrands LB, and Gansevoort RT
- Subjects
- Humans, COVID-19 Testing, Renal Dialysis adverse effects, Proportional Hazards Models, Peritoneal Dialysis adverse effects, Kidney Failure, Chronic diagnosis, Kidney Failure, Chronic therapy, COVID-19 epidemiology, COVID-19 therapy
- Abstract
Background: The clinical course of COVID-19 in peritoneal dialysis (PD) patients has so far only been analysed in relatively small, often single-centre case series. Therefore, we studied patient- and disease-related characteristics and outcomes of COVID-19 in a larger European cohort of PD patients., Methods: We used data from the European Renal Association COVID-19 Database (ERACODA) on PD and haemodialysis (HD) patients with COVID-19 (presentation between February 2020 and April 2021). Hazard ratios (HR) for mortality at 3 months were calculated using Cox proportional-hazards regression. In addition, we examined functional and mental health status among survivors at this time point as determined by their treating physician., Results: Of 216 PD patients with COVID-19, 80 (37%) were not hospitalised and 136 (63%) were hospitalised, of whom 19 (8.8%) were admitted to an intensive care unit. Mortality at 3 months for these subgroups was 18%, 40%, and 37%, respectively ( p = 0.0031). Compared with HD patients, PD patients had higher mortality (crude HR: 1.49; 95% CI: 1.33-1.66), even when adjusted for patient characteristics and disease severity (adjusted HR: 1.56; 95% CI: 1.39-1.75). Follow-up data on 67 of 146 patients who survived COVID-19 showed functional recovery to pre-COVID-19 levels in 52 (78%) and mental recovery in 58 patients (87%) at 3 months after the COVID-19 diagnosis., Conclusion: The mortality rate in the first 3 months after presentation with COVID-19 is high, especially among PD patients who were hospitalised. PD patients with COVID-19 had a higher mortality risk than HD patients. The majority of surviving patients recovered both functionally and mentally from COVID-19 within 3 months.
- Published
- 2023
- Full Text
- View/download PDF
44. Acquired cutis laxa from heavy chain deposition disease.
- Author
-
Gillion V, Vekemans MC, Rinsant A, Aydin S, Colmant C, Bridoux F, and Goffin E
- Subjects
- Humans, Cutis Laxa diagnosis, Multiple Myeloma, Heavy Chain Disease
- Published
- 2022
- Full Text
- View/download PDF
45. Safety, Efficacy, and Relapse of Nirmatrelvir-Ritonavir in Kidney Transplant Recipients Infected With SARS-CoV-2.
- Author
-
Devresse A, Sébastien Briol, De Greef J, Lemaitre F, Boland L, Haufroid V, Scohy A, Kabamba B, Yombi JC, Belkhir L, Darius T, Buemi A, De Potter K, Mantegazza R, Bearzatto B, Goffin E, and Kanaan N
- Abstract
Introduction: The efficacy of nirmatrelvir-ritonavir (NR; Paxlovid, Pfizer, New York, NY) to decrease the risk of progression to severe COVID-19 in high-risk patients has been demonstrated. However, evidence in infected kidney transplant recipients (KTRs) is lacking. Moreover, NR has significant and potentially harmful interactions with calcineurin inhibitors (CNIs)., Methods: In this single-center retrospective study, we included all KTRs treated with NR from April 28 to June 3, 2022. A standard management strategy of CNI dose adaptation (discontinuation of tacrolimus 12 hours before the start of NR and administration of 20% of the cyclosporine dose) and laboratory follow-up was applied., Results: A total of 14 patients were included. Compared with day-0 (day before NR initiation), day-7 plasma creatinine concentrations and SARS-CoV-2 viral loads were similar ( P = 0.866) and decreased ( P = 0.002), respectively. CNI trough concentrations at the end of the treatment were satisfactory, nonetheless, with high individual variability. After a median follow-up time of 34 days, no death or viral pneumonia were observed. Nevertheless, 2 patients experienced early SARS-CoV-2 infection relapses (at day-10 and day-21) associated with an increase in SARS-CoV-2 viral loads., Conclusion: NR can be used in KTRs but requires a strict protocol of drug adaptation. We observed 2 cases of early relapse after NR treatment that need further investigations., (© 2022 International Society of Nephrology. Published by Elsevier Inc.)
- Published
- 2022
- Full Text
- View/download PDF
46. Impact of Recipient Obesity on Kidney Transplantation Outcome: A Retrospective Cohort Study with a Matched Comparison.
- Author
-
Buemi A, Romero L, Zech F, Darius T, De Meyer M, Devresse A, Kanaan N, Goffin E, and Mourad M
- Subjects
- Humans, Retrospective Studies, Treatment Outcome, Graft Survival, Obesity complications, Postoperative Complications epidemiology, Postoperative Complications etiology, Body Mass Index, Risk Factors, Kidney Transplantation adverse effects, Diabetic Nephropathies complications
- Abstract
Background: The aim of this study was to evaluate the effect of a recipient's obesity on posttransplant complications and patient and graft survival., Methods: A single-institution, retrospective study was performed on obese renal transplant recipients (BMI ≥ 30 kg/m
2 , n = 102) from January 2010 to December 2018, matched with non-obese recipients (BMI < 30 kg/m2 , n = 204). For comparison, for every obese patient we selected 2 nonobese patients with a similar age, sex, and period of transplantation. The comparative analysis included patient and graft survival as primary outcomes and graft function and postoperative complications as a secondary outcome., Results: Recipient demographics were comparable in both groups except for diabetic nephropathy in obese patients (P = .0006). Obesity was strongly related to a poorer patient survival (risk ratio [RR] = 2.83 confidence interval [CI] 95% 1.14-7.04; P = .020) but there was no observed difference in graft survival (P = .6). While early graft function was inferior in the obese population (RR = 2.41; CI 95% 1.53-3.79; P = .00016), during late follow-up, no statistically significant differences were observed between both groups (P = .36). Obese recipients had a significantly higher risk of delayed graft function (RR = 1.93; CI 95% (1.19-3.1), P = .0077), heart infarction (RR = 7; CI 95% 1.68-29.26; P = .0042), wound infections (RR = 8; CI 95% 1.96-32.87; P = .0015), diabetes aggravation (RR = 3.13; CI 95% 1.29-7.6; P = .011), and surgical revision for eventration (RR = 8; CI 95% 1.22-52.82; P = .026) when compared with nonobese recipients., Conclusions: Despite the inferior early kidney graft function in obese recipients, there was no difference observed at the long-term follow-up. However, recipient obesity demonstrated a negative effect on patient survival and postoperative complications., (Copyright © 2022 Elsevier Inc. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
47. A Single Oral Immunization with Replication-Competent Adenovirus-Vectored Vaccine Induces a Neutralizing Antibody Response in Mice against Canine Distemper Virus.
- Author
-
Du X, Goffin E, Gillard L, Machiels B, and Gillet L
- Subjects
- Adenoviridae genetics, Animals, Antibodies, Neutralizing, Antibodies, Viral, Dogs, Humans, Immunization, Mice, Mice, Inbred BALB C, Vaccination, Adenoviridae Infections, Adenovirus Vaccines, Distemper prevention & control, Distemper Virus, Canine physiology, Viral Vaccines
- Abstract
Canine Distemper Virus (CDV) is a fatal and highly contagious pathogen of multiple carnivores. While injectable vaccines are very effective in protecting domestic animals, their use in the wild is unrealistic. Alternative vaccines are therefore needed. Adenovirus (AdV) vectors are popular vaccine vectors due to their capacity to elicit potent humoral and cellular immune responses against the antigens they carry. In parallel, vaccines based on live human AdV-4 and -7 have been used in U.S. army for several decades as replicative oral vaccines against respiratory infection with the same viruses. Based on these observations, the use of oral administration of replication competent AdV-vectored vaccines has emerged as a promising tool especially for wildlife vaccination. Developing this type of vaccine is not easy, however, given the high host specificity of AdVs and their very low replication in non-target species. To overcome this problem, the feasibility of this approach was tested using mouse adenovirus 1 (MAV-1) in mice as vaccine vectors. First, different vaccine vectors expressing the entire or part H or F proteins of CDV were constructed. These different strains were then used as oral vaccines in BALB/c mice and the immune response to CDV was evaluated. Only the strain expressing the full length CDV H protein generated a detectable and neutralizing immune response to CDV. Secondly, using this strain, we were able to show that although this type of vaccine is sensitive to pre-existing immunity to the vector, a second oral administration of the same vaccine is able to boost the immune response against CDV. Overall, this study demonstrates the feasibility of using replicating AdVs as oral vaccine vectors to immunize against CDV in wildlife carnivores.
- Published
- 2022
- Full Text
- View/download PDF
48. In Reply to 'Kidney Transplant Recipients With COVID-19 and Monoclonal Antibody Therapy: Additional Considerations'.
- Author
-
Fernandes G, Devresse A, Scohy A, De Greef J, Yombi JC, Belkhir L, Darius T, Mourad M, Buemi A, Kabamba B, Goffin E, and Kanaan N
- Published
- 2022
- Full Text
- View/download PDF
49. Repetitive saliva-based mass screening as a tool for controlling SARS-CoV-2 transmission in nursing homes.
- Author
-
Saegerman C, Donneau AF, Speybroeck N, Diep AN, Williams A, Stamatakis L, Coppieters W, Michel F, Breuer C, Dandoy M, Ek O, Gourzones C, Schyns J, Goffin E, Minner F, Renault V, Gillet L, and Bureau F
- Subjects
- Animals, COVID-19 Testing veterinary, Clinical Laboratory Techniques methods, Clinical Laboratory Techniques veterinary, Humans, Mass Screening veterinary, Nursing Homes, Pandemics prevention & control, Saliva, COVID-19 diagnosis, COVID-19 epidemiology, COVID-19 veterinary, SARS-CoV-2
- Abstract
Nursing home (NH) residents and staff have been severely affected by the COVID-19 pandemic. The aim of this study was to examine the use of weekly saliva RT-qPCR testing for SARS-CoV-2 detection among NH workers as a strategy to control disease transmission within NHs in Belgium. From 16 November to 27 December 2020, a voluntary and anonymous weekly screening was implemented in a cohort of 50,000 workers across 572 NHs in the Walloon region of Belgium to detect asymptomatic cases of SARS-CoV-2 via saliva RT-qPCR testing and using the Diagenode saliva sample collection device. Positive workers were isolated to avoid subsequent infections in residents and other staff. RT-qPCR testing was based on pooled saliva sampling techniques from three workers, followed by individual testing of each positive or inconclusive pool. The majority of NHs (85%) and 55% of their workers participated. Pooling did not affect sensitivity as it only induced a very decrease in sensitivity estimated as 0.33%. Significant decreases in the prevalence (34.4-13.4%) and incidence of NHs with either single (13.8-2%) or multiple positive workers (3.7-0%) were observed over time. In addition, deaths among NH residents and NH worker absences decreased significantly over time. Weekly saliva RT-qPCR testing for SARS-CoV-2 demonstrated large-scale feasibility and efficacy in disrupting the chain of transmission. Implementation of this testing strategy in NHs could also be extended to other settings with the aim to control viral transmission for maintaining essential activities., (© 2021 Wiley-VCH GmbH.)
- Published
- 2022
- Full Text
- View/download PDF
50. Characteristics, practices, and outcomes in a Belgian cohort of incident home hemodialysis patients: A 6-year experience.
- Author
-
Vô B, Anthonissen B, Verger C, Jadoul M, Morelle J, and Goffin E
- Subjects
- Belgium epidemiology, Cohort Studies, Hemodialysis, Home adverse effects, Hemodialysis, Home methods, Humans, Male, Middle Aged, Renal Dialysis methods, Arteriovenous Fistula, Kidney Failure, Chronic therapy
- Abstract
Background: Home hemodialysis (HHD) remains underused in patients with kidney failure. Current literature on HHD mostly originates from non-European countries, making generalization difficult. The present study describes patients' profile and practice patterns from a Belgian HHD center, and assesses patient and technique survival and complications associated with HHD., Methods: We analyzed data from all our incident patients during a 6-year period. The patient's characteristics were summarized using descriptive statistics. Transition to another therapeutic modality, estimated using a risk model with death and transplantation as competing events, episodes of respite cares and hospitalizations, and access complications were analyzed., Results: Eighty patients (mean age: 47 years; male: 64%) met the inclusion criteria. Fifty-one percent of patients initiated dialysis with a central venous catheter (CVC) and 96% were not assisted. Arterio-venous fistula (AVF) cannulation was performed using buttonhole technique. Standard-frequent HD (47%) and short-frequent low-flow dialysate HD (34%) were mostly used at HHD initiation. Cumulative incidences of technique failure and death were 15%, 24%, and 32% at 1, 2, and 5 years. Incidence rates for respite dialysis and hospitalizations were 2.39 and 0.54 per patient-year of HHD. In comparison with AVF, incidence rate ratios of overall access complications and access-related infections for CVC were 4.3 (95% CI: 3.1-6, p < 0.01) and 4.4 (95% CI: 2.1-10, p < 0.01), respectively. Buttonhole cannulation was complicated by 0.26 (95% CI: 0.15-0.46) infections per 1000 AVF-days., Conclusions: This present study provides important information about patient's profile and practice patterns and safety in a cohort of 80 incident Belgian HHD patients, with encouraging techniques and patient survival., (© 2022 International Society for Hemodialysis.)
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.